Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer ...

In this video, Nancy U. Lin, MD, discusses curative intent research in HER2-positive metastatic breast cancer.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Discover essential antibody purification methods, from affinity chromatography to ion exchange chromatography, for research ...

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.